

ASX ANNOUNCEMENT

1 April 2025

CONNEQT EXPANDS HEART HEALTH ACCESS WITH APPLE HEALTH APP INTEGRATION ON IPHONE

Cardiex Limited (ASX: CDX) (the **Company**), a leading cardiovascular health company, today announced that customers of its CONNEQT Health ("CONNEQT") subsidiary can now access key arterial health biomarkers directly through the Apple Health app on iPhone. This integration is part of CONNEQT's ongoing commitment to empower patients with easy, secure access to their personal health information.

Through this new capability, patients with a CONNEQT Pulse monitor, paired with the CONNEQT App, can seamlessly connect their account to the Apple Health app. Once connected, select biomarker results are automatically updated and accessible within the Health Records section of the app. This allows users to view their data in one convenient and secure location on their iPhone in addition to the CONNEQT App.

Cardiex CEO Craig Cooper commented:

"CONNEQT is committed to delivering a more connected and personalized healthcare experience. By integrating with Apple Health Records, we are putting important health information at our patients' fingertips, helping them make informed decisions and manage their health more effectively.

Initially we are launching our integration with both brachial blood pressure and clinical grade heart rate, followed in the near term with further integrations of a full suite of biomarkers based on our market leading SphygmoCor ® technology."

All health data is encrypted and secure, protected by the user's iPhone passcode, Touch ID, or Face ID. CONNEQT's integration with Apple Health Records adheres to the highest standards of privacy and security, ensuring patients retain control over their personal information.

This integration is available now to all CONNEQT Pulse users in the USA using iOS devices with the latest version of Apple Health. To get started, customers can use the Health app to search for CONNEQT under available health systems.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

Media Relations Melissa Hamilton melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor[®] vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").